Spectrum Pharmaceuticals, Inc. (SPPI)
Price:
1.02 USD
( - -0.01 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.
NEWS
SPECTRUM FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit Filed Against Spectrum Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Before September 24th
globenewswire.com
2025-09-23 18:19:00Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Spectrum (SPPI) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Spectrum between March 17, 2022 to September 22, 2022 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Spectrum Pharmaceuticals (SPPI) and Assertio Holdings (ASRT) Investor Alert: FINAL DEADLINE in Securities Lawsuit– Hagens Berman
globenewswire.com
2025-09-23 16:37:00SAN FRANCISCO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development offers a new opportunity for investors to represent the class after the previously appointed lead plaintiff was disqualified on August 4, 2025. The new deadline to apply is September 24, 2025.
CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Spectrum Pharmaceuticals (NASDAQ: SPPI) Investors to Inquire About a Securities Fraud Class Action by September 24, 2025
prnewswire.com
2025-09-23 08:36:00PHILADELPHIA , Sept. 23, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the "Class Period").
SPPI FINAL DEADLINE: ROSEN, TOP RANKED INVESTOR RIGHTS COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important September 24 Deadline in Securities Class Action – SPPI
globenewswire.com
2025-09-22 17:25:00NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the “Class Period”), of the important September 24, 2025 lead plaintiff deadline. The lead plaintiff process was reopened by the Court.
SPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
prnewswire.com
2025-09-22 04:26:00LOS ANGELES , Sept. 22, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ("Spectrum" or "the Company") (NASDAQ: SPPI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
SPPI Deadline: Rosen Law Firm Urges Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
businesswire.com
2025-09-21 18:07:00NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the “Class Period”). The lead plaintiff process was reopened by the Court. Spectrum Pharmaceuticals describes itself as a “biopharmaceutical company focused on acquiring, developing, and commercializ.
Spectrum Pharmaceuticals (SPPI) and Assertio Holdings (ASRT) Investor Alert: 3-DAY DEADLINE in Securities Lawsuit– Hagens Berman
globenewswire.com
2025-09-21 11:23:00SAN FRANCISCO, Sept. 21, 2025 (GLOBE NEWSWIRE) -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development offers a new opportunity for investors to represent the class after the previously appointed lead plaintiff was disqualified on August 4, 2025. The new deadline to apply is September 24, 2025.
SPPI Deadline: SPPI Investors with Losses in Excess of $100K Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit
prnewswire.com
2025-09-20 14:00:00NEW YORK , Sept. 20, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the "Class Period"), of the important September 24, 2025 lead plaintiff deadline.
SPPI DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important September 24 Deadline in Securities Class Action – SPPI
globenewswire.com
2025-09-19 17:26:00NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the “Class Period”), of the important September 24, 2025 lead plaintiff deadline. The lead plaintiff process was reopened by the Court.
SPECTRUM DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit Filed Against Spectrum Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Before September 24th
globenewswire.com
2025-09-19 10:41:00Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Spectrum (SPPI) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Spectrum between March 17, 2022 to September 22, 2022 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Spectrum Pharmaceuticals (SPPI) and Assertio Holdings (ASRT) Investor Alert: 6-DAY DEADLINE in Securities Lawsuit – Hagens Berman
globenewswire.com
2025-09-19 09:50:00SAN FRANCISCO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development offers a new opportunity for investors to represent the class after the previously appointed lead plaintiff was disqualified on August 4, 2025. The new deadline to apply is September 24, 2025.
DEADLINE NEXT WEEK: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Contact the Firm Before September 24, 2025
globenewswire.com
2025-09-18 17:06:00PHILADELPHIA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) (“Spectrum” or the “Company”) on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the “Class Period”).
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important September 24 Deadline in Securities Class Action – SPPI
globenewswire.com
2025-09-16 16:41:00NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the “Class Period”), of the important September 24, 2025 lead plaintiff deadline. The lead plaintiff process was reopened by the Court.
DEADLINE APPROACHING: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Inquire About a Securities Fraud Class Action by September 24, 2025
prnewswire.com
2025-09-12 11:51:00PHILADELPHIA , Sept. 12, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the "Class Period").
SPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit
prnewswire.com
2025-09-10 18:17:00NEW YORK , Sept. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the "Class Period"), of the important September 24, 2025 lead plaintiff deadline.
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPPI
globenewswire.com
2025-09-10 15:56:00NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the “Class Period”), of the important September 24, 2025 lead plaintiff deadline. The lead plaintiff process was reopened by the Court.
SPECTRUM FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit Filed Against Spectrum Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Before September 24th
globenewswire.com
2025-09-23 18:19:00Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Spectrum (SPPI) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Spectrum between March 17, 2022 to September 22, 2022 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Spectrum Pharmaceuticals (SPPI) and Assertio Holdings (ASRT) Investor Alert: FINAL DEADLINE in Securities Lawsuit– Hagens Berman
globenewswire.com
2025-09-23 16:37:00SAN FRANCISCO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development offers a new opportunity for investors to represent the class after the previously appointed lead plaintiff was disqualified on August 4, 2025. The new deadline to apply is September 24, 2025.
CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Spectrum Pharmaceuticals (NASDAQ: SPPI) Investors to Inquire About a Securities Fraud Class Action by September 24, 2025
prnewswire.com
2025-09-23 08:36:00PHILADELPHIA , Sept. 23, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the "Class Period").
SPPI FINAL DEADLINE: ROSEN, TOP RANKED INVESTOR RIGHTS COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important September 24 Deadline in Securities Class Action – SPPI
globenewswire.com
2025-09-22 17:25:00NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the “Class Period”), of the important September 24, 2025 lead plaintiff deadline. The lead plaintiff process was reopened by the Court.
SPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
prnewswire.com
2025-09-22 04:26:00LOS ANGELES , Sept. 22, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ("Spectrum" or "the Company") (NASDAQ: SPPI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
SPPI Deadline: Rosen Law Firm Urges Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
businesswire.com
2025-09-21 18:07:00NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the “Class Period”). The lead plaintiff process was reopened by the Court. Spectrum Pharmaceuticals describes itself as a “biopharmaceutical company focused on acquiring, developing, and commercializ.
Spectrum Pharmaceuticals (SPPI) and Assertio Holdings (ASRT) Investor Alert: 3-DAY DEADLINE in Securities Lawsuit– Hagens Berman
globenewswire.com
2025-09-21 11:23:00SAN FRANCISCO, Sept. 21, 2025 (GLOBE NEWSWIRE) -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development offers a new opportunity for investors to represent the class after the previously appointed lead plaintiff was disqualified on August 4, 2025. The new deadline to apply is September 24, 2025.
SPPI Deadline: SPPI Investors with Losses in Excess of $100K Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit
prnewswire.com
2025-09-20 14:00:00NEW YORK , Sept. 20, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the "Class Period"), of the important September 24, 2025 lead plaintiff deadline.
SPPI DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important September 24 Deadline in Securities Class Action – SPPI
globenewswire.com
2025-09-19 17:26:00NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the “Class Period”), of the important September 24, 2025 lead plaintiff deadline. The lead plaintiff process was reopened by the Court.
SPECTRUM DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit Filed Against Spectrum Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Before September 24th
globenewswire.com
2025-09-19 10:41:00Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Spectrum (SPPI) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Spectrum between March 17, 2022 to September 22, 2022 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Spectrum Pharmaceuticals (SPPI) and Assertio Holdings (ASRT) Investor Alert: 6-DAY DEADLINE in Securities Lawsuit – Hagens Berman
globenewswire.com
2025-09-19 09:50:00SAN FRANCISCO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development offers a new opportunity for investors to represent the class after the previously appointed lead plaintiff was disqualified on August 4, 2025. The new deadline to apply is September 24, 2025.
DEADLINE NEXT WEEK: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Contact the Firm Before September 24, 2025
globenewswire.com
2025-09-18 17:06:00PHILADELPHIA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) (“Spectrum” or the “Company”) on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the “Class Period”).
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important September 24 Deadline in Securities Class Action – SPPI
globenewswire.com
2025-09-16 16:41:00NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the “Class Period”), of the important September 24, 2025 lead plaintiff deadline. The lead plaintiff process was reopened by the Court.
DEADLINE APPROACHING: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Inquire About a Securities Fraud Class Action by September 24, 2025
prnewswire.com
2025-09-12 11:51:00PHILADELPHIA , Sept. 12, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the "Class Period").
SPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit
prnewswire.com
2025-09-10 18:17:00NEW YORK , Sept. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the "Class Period"), of the important September 24, 2025 lead plaintiff deadline.
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPPI
globenewswire.com
2025-09-10 15:56:00NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the “Class Period”), of the important September 24, 2025 lead plaintiff deadline. The lead plaintiff process was reopened by the Court.